<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901546</url>
  </required_header>
  <id_info>
    <org_study_id>58102</org_study_id>
    <nct_id>NCT04901546</nct_id>
  </id_info>
  <brief_title>Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome</brief_title>
  <official_title>Esophageal Atresia: a Natural Experiment of the Effects of Oral Inoculation on the Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thrasher Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to understand changes of the gut microbiome due to esophageal&#xD;
      atresia. The intervention will be to give a patient his or her own saliva through their&#xD;
      gastrostomy tube (directly into the stomach) to observe if this can normalize microbial&#xD;
      colonization of the gut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After being informed about the study and its overall risks, parents will be given the option&#xD;
      to enroll their infant. Participants (infants) with esophageal atresia and a gastrostomy tube&#xD;
      will be given their own saliva through their gastrostomy tube, directly into the stomach.&#xD;
      Samples of saliva and stool will be collected from these infants, and from a comparison group&#xD;
      without esophageal atresia, as well as blood and urine to look for changes in immune&#xD;
      responses and in metabolism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">May 15, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Infants with esophageal atresia (EA) and comparison infants without esophageal atresia (but also in the neonatal intensive care unit, NICU) will be recruited. Infants with EA will be given their own saliva for 1 week, with every feed. Infants without EA will receive usual care. All subjects will have samples collected according to the same schedule.&#xD;
Mothers of infants will also be recruited and have samples collected in order to understand the sources of the infant's gut microbiome.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Gut Microbial Community Structure</measure>
    <time_frame>From birth until discharge from the hospital, up to 1 year</time_frame>
    <description>Evaluate community structure and differential abundances of dominant taxa and of key taxa to the newborn (e.g., Bifidobacterium, Bacteroides, Lactobacillus, Staphylococcus and Enterobacteriaceae)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Immune System Profile</measure>
    <time_frame>From birth until discharge from the hospital, up to 1 year</time_frame>
    <description>Determine immune cell profiles using mass cytometry (CyTOF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Fecal Metabolome Profile</measure>
    <time_frame>From birth until discharge from the hospital, up to 1 year</time_frame>
    <description>Measure metabolites in the stool using mass spectrometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Metabolome Profile</measure>
    <time_frame>From birth until discharge from the hospital, up to 1 year</time_frame>
    <description>Measure metabolites in the blood using mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophageal Atresia</condition>
  <arm_group>
    <arm_group_label>Infants with Esophageal Atresia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting at 3 weeks, infants will be administered 1 mL of their own saliva via gastrostomy tube, with each feed (8x/day) for one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparison Infants without Esophageal Atresia</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Infants do not have EA and thus can swallow their own saliva.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient's own saliva</intervention_name>
    <description>Infants with esophageal atresia will be given their own saliva</description>
    <arm_group_label>Infants with Esophageal Atresia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Neonates with Esophageal Atresia (All, no exclusion criteria); maximum age at&#xD;
             enrollment is 3 months.&#xD;
&#xD;
          -  Neonates matched for gestational age without EA, also anticipated to require surgery&#xD;
             (Infants &gt;=32 weeks), or also premature (&lt;32 weeks)&#xD;
&#xD;
        Exclusion Criteria (only for infants without EA):&#xD;
&#xD;
          -  sepsis&#xD;
&#xD;
          -  admission to study hospital after 7 days old&#xD;
&#xD;
          -  expected length of stay &lt;2 weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Relman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pearl Houghteling</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lucile Packard Children's Hospital</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 21, 2021</study_first_submitted>
  <study_first_submitted_qc>May 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>May 20, 2021</last_update_submitted>
  <last_update_submitted_qc>May 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>David A. Relman</investigator_full_name>
    <investigator_title>Professor, Medicine - Infectious Disease</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Atresia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

